HCW Biologics (NASDAQ:HCWB) Posts Earnings Results, Misses Estimates By $0.18 EPS

HCW Biologics (NASDAQ:HCWB) announced its earnings results on Tuesday. The company reported ($1.02) earnings per share for the quarter, missing the consensus estimate of ($0.84) by ($0.18), FiscalAI reports. The business had revenue of $0.03 million for the quarter, compared to the consensus estimate of $7.01 million.

HCW Biologics Stock Performance

Shares of HCW Biologics stock traded down $0.00 during trading hours on Tuesday, hitting $0.36. The company’s stock had a trading volume of 394,144 shares, compared to its average volume of 25,039,006. The stock has a market cap of $1.27 million, a price-to-earnings ratio of -0.03 and a beta of 0.79. HCW Biologics has a twelve month low of $0.34 and a twelve month high of $17.80. The firm has a fifty day moving average of $0.77 and a 200-day moving average of $2.04.

Institutional Trading of HCW Biologics

An institutional investor recently bought a new position in HCW Biologics stock. Armistice Capital LLC bought a new position in shares of HCW Biologics Inc. (NASDAQ:HCWB) during the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm bought 300,180 shares of the company’s stock, valued at approximately $291,000. Armistice Capital LLC owned about 9.15% of HCW Biologics at the end of the most recent quarter. Institutional investors and hedge funds own 2.96% of the company’s stock.

Analyst Upgrades and Downgrades

Separately, Weiss Ratings restated a “sell (e+)” rating on shares of HCW Biologics in a research report on Thursday, January 22nd. One equities research analyst has rated the stock with a Buy rating and one has given a Sell rating to the company. According to MarketBeat.com, HCW Biologics has an average rating of “Hold” and a consensus price target of $35.00.

About HCW Biologics

HCW Biologics Inc, a clinical-stage biopharmaceutical company, focuses on discovering and developing novel immunotherapies for chronic, low-grade inflammation, and age-related diseases in the United States. The company's lead products include HCW9218, which is in Phase 1 clinical chemo-refractory/chemo-resistant solid tumors with pancreatic, ovarian, breast, prostate, and colorectal cancers, as well as Phase 2 clinical trial with metastatic advanced stage ovarian cancer patients; and HCW9302 for autoimmune and proinflammatory diseases, such as alopecia areata diseases.